In the News
Keep up to date with the latest news articles from around the world.
Articles represent the views of their authors and not ME/CFS SA. Always seek advice from a registered health practitioner before changing your care plan.
01 March, 2024
Chronic Fatigue Syndrome Is A Physiological (And Not Psychosomatic) Condition
Scientists have made a breakthrough in understanding chronic fatigue syndrome, a debilitating condition that affects millions of people worldwide. A recent study published in Nature Communications reveals the physiological basis of the disease, shedding light on the immune system, brain activity, and cardiorespiratory functions underlying the symptoms.
01 March, 2024
Lying Demo In Frankfurt: Solidarity For ME/CFS Sufferers
Joannes and Stephanie van der Linden came to Frankfurt from Friedberg to represent their son. “I go for Maarten Maria, invisible due to ME/CFS” is written on pieces of paper that they hold up. Maarten’s sisters are also demonstrating, and even the dog Frida has a piece of paper tied to her. The 22-year-old Maarten himself cannot be there in downtown Frankfurt, and he is otherwise excluded from everything that makes up a young man’s life. He suffers from severe chronic fatigue syndrome ME/CFS and has been in bed in the dark around the clock for a year and a half.
01 March, 2024
Clues To A Better Understanding Of Chronic Fatigue Syndrome Emerge From A Major Study
After seven years, research was published in Nature Communications. It gives an unusually exhaustive look at the biological abnormalities that can arise in ME/CFS, spanning the brain, the gut, the immune system and the autonomic nervous system.
29 February, 2024
Identifying The Mental Health Burden In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients In Switzerland: A Pilot Study
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating chronic disease of significant public health and clinical importance. It affects multiple systems in the body and has neuro-immunological characteristics. The disease is characterized by a prominent symptom called post-exertional malaise (PEM), as well as abnormalities in the immune-inflammatory pathways, mitochondrial dysfunctions and disturbances in neuroendocrine pathways. The purpose of this study was to evaluate the impact of ME/CFS on the mental health and secondary psychosocial manifestations of patients, as well as their coping mechanisms.
29 February, 2024
'It Took The Rug Right Out From Under My Life': Milestone ME/CFS Study Begins To Explain Disease, But Will It Lead To Treatments?
An NIH study many years in the making starts to unravel the biology of a misunderstood disease called ME/CFS.
29 February, 2024
Olga Sukhovskaya: “With Burnout, It Is Important To Look At The Ways You Gain Your Energy Back”
Olga Sukhovskaya is a mental health specialist who works as a trainer and assessor in the VET sector (MH and Community Services). Olga told SBS Russian talked about chronic fatigue syndrome and burnout and adaptation of migrants in a new country.
28 February, 2024
Study Offers Clues About The Cause Of Chronic Fatigue Syndrome Post Infection
Researchers have found differences in the brains and immune systems of people who have chronic fatigue syndrome after an infection. According to the researchers, the findings, for the first time, suggest a link between specific abnormalities or imbalances in the brain and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome (PI-ME/CFS).
28 February, 2024
Long COVID-19 Is Linked To Chronic Pain Conditions
Therapies for pain conditions like fibromyalgia provide clues for helping those with long COVID.
28 February, 2024
Managing Pain Should Be More Than ‘Hammering Patients With Immunomodulatory Medications’
SCOTTSDALE, Ariz. — Understanding the science of pain can help rheumatologists better manage fibromyalgia and other chronic conditions, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.
27 February, 2024
Tonix Pharmaceuticals' Fibromyalgia Trial Shows Promising Results In Webinar Presentation
Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share positive Phase 3 data on Tonmya, also known as TNX-102 SL, for the management of fibromyalgia, and discussed the company's plans to file for FDA approval in the second half of 2024. Dr. Lederman highlighted that Tonmya, a centrally acting, non-opioid, non-addictive bedtime medication, showed promising results in the RESILIENT Phase 3 study.
